


**Purpose**

- In recent years, gabapentin has been reclassified as a Schedule V drug by some states.
- Jail and prison formularies have removed gabapentin as a result of this reclassification.
- We aim to highlight the adverse effects patients may experience because of this legislative decision.

**Background**

- Both gabapentin and cyclobenzaprine are used to treat neuropathic pain
- Cyclobenzaprine's structure is similar to tricyclic anti-depressants like amitriptyline and shares many of the same side effects.



**Case**

- A 23-year-old federally incarcerated male with relevant past medical history of severe thoracic kyphoscoliosis presented to the ED with one week history of altered mental status.
- Patient reported that he 'saw a person with a gun' in his cell, was being chased in the woods, and felt paranoid. Reported 'good' mood and that he had been awake the past few nights.
- One week prior, patient's gabapentin for back pain was discontinued and changed to Flexeril (cyclobenzaprine) 10 mg TID.
- On exam, he had mildly increased rate of speech with tangential thought processes.
- Patient's urine drug screen was negative
- No past history of mood disorders or psychosis in the patient or his family.
- One day after providers held his cyclobenzaprine, the patient reported no further symptoms

**Discussion**

- Given the onset and resolution of this patient's symptoms coinciding with his cyclobenzaprine course, his symptoms are most likely iatrogenic.
- The similar side effect profiles of cyclobenzaprine and amitriptyline may be attributable to their chemical structures only differing in one double bond.
- Reclassification of gabapentin as a Schedule V drug may continue to effect prescription decision-making.
- The benefits of lower abuse potential must be weighed against the risk of psychotic symptoms when changing from gabapentin to cyclobenzaprine.

**References**

- Cohen, J. Y., & Guilbault, A. (2018). Induction of Psychosis by Cyclobenzaprine. *Psychopharmacology bulletin*, 48(4), 15-19.
- Douglas MA, Levine DP. Hallucinations in an Elderly Patient Taking Recommended Doses of Cyclobenzaprine. *Arch Intern Med*. 2000;160(9):1373.
- GIBBS, J. J. (1987). Symptoms of Psychopathology among Jail Prisoners: The Effects of Exposure to the Jail Environment. *Criminal Justice and Behavior*, 14(3), 288-310.
- Premont, Makaela, PharmD. GoodRx. (n.d.). *Is gabapentin a controlled substance? in some states, yes*. GoodRx. Published July 16, 2022. Retrieved January 23, 2023, from <https://www.goodrx.com/gabapentin/is-gabapentin-a-controlled-substance>
- Santucci, Karen. "Psychiatric disease and drug abuse." *Current opinion in pediatrics* vol. 24,2 (2012): 233-7. doi:10.1097/MOP.0b013e3182504b6f
- Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. 1998. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995